Founded in 2015, by Melvin Glapion, Mithra Forensic Research is an independent investment research firm based in Los Angeles California. Mithra Forensic Research primarily focuses on identifying companies with flawed and deteriorating business fundamentals as well as those companies engaging in aggressive accounting and financial statement fraud.
Mithra Forensic Research relies upon a proprietary quantitative model which is used to identify companies showing signs of financial statement deterioration or evidence of aggressive accounting. We then conduct a more detailed analysis of only those companies highlighted as offering the greatest potential for significant price movement in the next 18 to 24 months.
During the IPO season Francis Gaskins, editor of IPOdesktop.com & director of research for Equities.com, regularly appears on CNBC TV, Bloomberg, thestreet.com & other financial cable channels. On the day of the Visa IPO he appeared on four cable TV financial shows including Bloomberg & CNBC.
Over the past five years he has been quoted over 500 times by such financial media as the Wall Street Journal, Bloomberg, Reuters, Associated Press, USA Today among others. Those quotes are available at IPOdesktop.com.
His varied personal interests include violin playing. For example, he is concertmaster of the Palisades Symphony. He also holds an MBA from Harvard Business School (finance) and an AB from Princeton University (economics).
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Our investment philosophy primarily resides in buying equities for long term investments. However, we do enter trading positions primarily in the options and futures market to take advantage of situations as they arise (VIX and energy trades).
Our background includes:
-Applied science perspective with an Engineering background
-Health science perspective with a Registered Nurse background
-Finance perspective with an MBA background
An experienced research and advisory team of Traders and Forecasters have combined to offer free research, forecasts, and trading ideas at StockReversals.com. Go to the website to subscribe for free. We also offer StockReversalsPremium.com which offers a combination Swing Trading with a focus on fundamentals and technicals, some long term growth stock profiles with massive upside potential and stunningly accurate SP 500 and Gold forecast models. Seeking Alpha Certified and Frequent Contributor to numerous financial websites. We specialize in behavioral analysis as it applies to market patterns and reversal trends. These trends happen over short term, intermediate, and long term time frames. We help our free subscribers with Business Disruptor growth stocks that crush the market. Sample picks include FB, YY, MOMO, AQMS, YIN, BLUE, KITE and many more. In our first 6 months we had 6 doubles, 1 triple, and 16 of 19 companies up 30-50% or more. Our work centers around a combination of Elliott Wave Theory, Technical Analysis, Human Behaviors, Sentiment, and Business Disruption analysis. We have advisory clients from around the world. South Korea, Australia, Canada, Sweden, Germany, The Netherlands and of course the U.S. We give away our service for free because of the laws of nature which we have on our website: “The possession of knowledge, unless accompanied by the manifestation and expression in sharing is a vain and foolish thing. The Law of Use is universal, and he who violates it suffers by reason of his conflict with natural forces.” Join us today at stockreversals.com and sign up for free.
I am a 40-something entrepreneur and executive, managing my own portfolio. I have been an Internet entrepreneur, founding and running VC-backed companies. For a little less than ten years I managed several global lines of business as Managing Director for a large management consultancy, where my teams supported primarily senior executives at global 2000 firms. My passion is creating and learning, and I am intensely interested in understanding all aspects of how businesses work, grow, succeed and fail.
I am currently an undergraduate student majoring in Finance and Computer Science. I plan on writing articles with a focus on growth companies and the TMT sector. I have been investing for four years now primarily in REIT's and Tech companies where I have outperformed respective indices and the S&P500 as a whole.
To view a historical list of all the companies that have been the subject of my articles, please follow the link: https://docs.google.com/spreadsheets/d/170rHmTxaaFpcXyGFWiwYXn8py0g8m67eL10G-LVisxo/edit?usp=sharing
In the spreadsheet, you can have the ability to assess my track record and performance.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
I'm a radiologist by trade, but the goal is to leverage that medical knowledge as a competitive advantage in the markets. I aim to include all of the following in my analyses to ensure high quality: 1) quantitative estimates; 2) new information or inferences that are not already disseminated throughout the market; and 3) hypotheses that are testable, i.e. can be proved right or wrong. I have a serious allergy to question marks and will never, ever include one in an article title.
My dream is to co-found a biotech and bring a cure from the lab to the bedside. In the meantime, saving lives in clinical practice is a perfectly acceptable alternative.
Please note that all opinions I express on this website reflect my personal beliefs only and are completely independent of my current or past employers and/or affiliated institutions.
Former scientists and consultants doing trading and investing for side income. We like to develop and improvise rational frameworks to evaluating stocks and like looking for inefficiencies in the market. We like to identify the key value drivers and like developing easy to understand investment and trading strategies. See Seeking Alpha's policy on anonymous authors (http://seekingalpha.com/page/policy_anonymous_contributors).
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.